Pell Bio-Med Technology Co., Ltd. (TPE:6949)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
160.50
+3.00 (1.90%)
Jul 10, 2025, 1:35 PM CST
24.42%
Market Cap 9.37B
Revenue (ttm) 26.58M
Net Income (ttm) -379.89M
Shares Out 58.35M
EPS (ttm) -6.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 166,754
Average Volume 119,098
Open 157.00
Previous Close 157.50
Day's Range 156.50 - 162.00
52-Week Range 78.00 - 164.00
Beta n/a
RSI 71.37
Earnings Date Aug 13, 2025

About Pell Bio-Med Technology

Pell Bio-Med Technology Co., Ltd., a biomedical company, engages in the development of cell culture technologies and techniques for therapeutic applications. Its commercial products include good tissue practice laboratory infrastructure, adipose-derived stem cells (ADSC) for regenerative medicine, and CIK and DC-CIK against cancers. The company also develops medicines for various types of cancers, cell immunotherapy, and stem cell regenerative therapy technologies. In addition, it engages in the research and development of chimeric antigen rece... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2017
Country Taiwan
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 6949
Full Company Profile

Financial Performance

In 2024, Pell Bio-Med Technology's revenue was 19.63 million, an increase of 8.86% compared to the previous year's 18.03 million. Losses were -389.42 million, -2.34% less than in 2023.

Financial Statements

News

There is no news available yet.